Barrett Katz
Corporate Officer/Principal chez Cornell University
Fortune : - $ au 31/03/2024
Profil
Barrett Katz is currently a Professor at Cornell University and New York University.
He previously served as the Chief Executive Officer at Danube Pharmaceuticals, Inc. from 2008 to 2010.
He also held positions as the Chairman-Ophthalmology Department at George Washington University, Vice President-Medical Affairs & Medical Strategy at Oldtech, Inc. from 2004 to 2006, and Chief Medical Officer at Fovea Pharmaceuticals SA from 2006 to 2008.
Additionally, he has worked as a Vice President-Medical Affairs & Strategy at ERYTech Pharma SA and as a Member at Corporate Mortgage Solutions, Inc., the University of California, Berkeley, and The Children's Hospital Corp.
Dr. Katz has also held roles as a Principal at the Association of University Professors of Ophthalmology, The Association for Research in Vision & Ophthalmology, American Academy of Ophthalmology, Inc., and American Ophthalmological Society.
He is a Professor at Albert Einstein College of Medicine, Inc. Dr. Katz served as the Chief Medical Officer at Gensight Biologics SA from 2017 to 2019 and is currently the Chief Medical Officer at Viridian Therapeutics, Inc. until 2024.
He is also the President & Chief Medical Officer at Fortify Therapeutics, Inc. and the President & Chief Marketing Officer at Retinagenix Therapeutics, Inc. Dr. Katz holds an MBA from Rochester Christian University, an undergraduate degree from Case Western Reserve University, and a doctorate from Case Western Reserve University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 17/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Barrett Katz
| Sociétés | Poste | Début |
|---|---|---|
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | Corporate Officer/Principal | - |
| New York University | Corporate Officer/Principal | - |
Anciens postes connus de Barrett Katz
| Sociétés | Poste | Fin |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 08/01/2024 |
| GENSIGHT BIOLOGICS S.A. | Chief Tech/Sci/R&D Officer | 08/10/2019 |
Danube Pharmaceuticals, Inc.
 Danube Pharmaceuticals, Inc. BiotechnologyHealth Technology Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY. | Chief Executive Officer | 01/01/2010 |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Chief Tech/Sci/R&D Officer | - |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Chief Tech/Sci/R&D Officer | 01/01/2006 |
Formation de Barrett Katz
| Rochester Christian University | Masters Business Admin |
| Case Western Reserve University | Undergraduate Degree |
| Colgate University | Undergraduate Degree |
| Case Western Reserve University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
| Corporate Mortgage Solutions, Inc. | Finance |
Danube Pharmaceuticals, Inc.
Danube Pharmaceuticals, Inc. BiotechnologyHealth Technology Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY. | Health Technology |
The Children's Hospital Corp.
 The Children's Hospital Corp. Medical/Nursing ServicesHealth Services Children's Hospital Corp. engages in the provision of pediatric care services. It offers acupuncture, angioplasty, antibiotic allergy testing, audiogram, baclofen pump, biochemical genetic testing, blended diet, bone scan, brain scan, breast augmentation surgery, cardiac catheterization, cardiac MRI in children, chest reconstruction surgery, and CO2 laser treatment. The company was founded by Francis Henry Brown in 1869 and is headquartered in Boston, MA. | Health Services |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
| Association of University Professors of Ophthalmology | |
The Association for Research in Vision & Ophthalmology
 The Association for Research in Vision & Ophthalmology Miscellaneous Commercial ServicesCommercial Services The Association for Research in Vision & Ophthalmology operates an association focused on research in vision and ophthalmology. The non-profit company is based in Rockville, MD. | Commercial Services |
American Academy of Ophthalmology, Inc.
 American Academy of Ophthalmology, Inc. Miscellaneous Commercial ServicesCommercial Services American Academy of Ophthalmology, Inc. is the world's largest association of eye physicians and surgeons. The non-profit company is based in San Francisco, CA, and has subsidiaries in the United States. The company advocates for patients and the public and set standards for ophthalmic education. The organization provides information about managing a practice, clinical pearls, and how to thrive in residency for young ophthalmologists. The company also offers an Outstanding Humanitarian Service Award and have committees that are essential to the establishment and implementation of the organization's mission and strategic goals. The Academy's website, EyeSmart, provides information on eye diseases, treatments, news, and tips for lifelong eye health. The company also has a faculty development program for their annual meeting and offer a program called Eyecelerator that advances eye care innovation by connecting creative entrepreneurs with mission-driven investors and access to markets. | Commercial Services |
American Ophthalmological Society
 American Ophthalmological Society Miscellaneous Commercial ServicesCommercial Services The American Ophthalmological Society is an organization that aims to promote excellence in patient care, education, and research in the field of ophthalmology. The society is based in San Francisco, CA, and was founded in 1864 by Edward Delafield, Daniel Bennett St. John Roosa, and Henry Noyes. The private company addresses essential issues in medicine and advance the art and science of ophthalmology. The society holds annual meetings every third week of May each year, and they offer travel grants to non-members who wish to attend. Membership nominations are accepted until April 30th each year. | Commercial Services |
Fortify Therapeutics, Inc.
 Fortify Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Fortify Therapeutics, Inc. is a private company dedicated to developing a safe and effective treatment for patients with Leber's hereditary optic neuropathy (LHON), a rare mitochondrial genetic disorder that leads to loss of central vision predominantly in young adults. The company is based in Palo Alto, CA. LHON is driven by mutations in subunits of the NADH dehydrogenase complex, reducing the ability of the retinal cells to produce energy, resulting in their degeneration. Fortify Therapeutics is currently developing a localized therapy to bypass the dysfunctional metabolic pathway in this disease and provide an alternate source of energy to the retinal cells of LHON patients. | Health Technology |
| Retinagenix Therapeutics, Inc. |
